Chinese researchers develop immunotherapeutic agent for colon cancer
Release time:2024-05-21 11:53:42
TIANJIN, March 15 (Xinhua) -- Chinese researchers have developed a novel immunotherapeutic agent for 。
TIANJIN, March 15 (Xinhua) -- Chinese researchers have developed a novel immunotherapeutic agent for treating colon cancer, according to a recent article in the academic journal ACS Nano. In animal experiments, the agent, upon successful entry into tumor cells, can enhance T cell effector function to kill tumor cells and suppress colon tumor growth, according to Lu Chunwan from the School of Life Sciences of Tianjin University, one of the authors of the article. The agent can enhance tumor immunogenicity and inhibit colon tumor growth, with no significant impact on normal cells, said Lu. Colon cancer, characterized by its long latency period and high mortality rate, poses a severe threat to human health. Among various therapies, immunotherapy is considered one of the most promising treatment directions, according to Lu.
(Editor:Fu Bo)
Related articles
The fightback begins: Boss of London's Queen Mary University tells pro
A university boss has been praised after telling a pro-Gaza student mob he will not meet them until2024-05-21What to know about Hamas again raising the possibility of a 2
The Palestinian militant group Hamas has said for more than 15 years that it could accept a two-stat2024-05-21Marcus Rashford cannot be painted as an innocent victim when he is looking like the brash £315k
It's a bitter irony that a week in which Manchester United celebrated their 250th homegrown player m2024-05-21Long lines form and frustration grows as Cuba runs short of cash
HAVANA (AP) — Alejandro Fonseca stood in line for several hours outside a bank in Havana hoping to w2024-05-21Yvette Fielding says her Most Haunted co
Yvette Fielding claims her Most Haunted co-star Derek Acorah was a fake who tried to grope and kiss2024-05-21- LONDON (AP) — Liverpool conceded Michail Antonio’s late equalizer in a 2-2 draw with West Ham on Sat2024-05-21
atest comment